Investigating the outcomes of solar lentigo treatment using the Q-switched 532 nm Nd:YAG laser
نویسندگان
1 Cutaneous Leishmaniasis Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2 Cutaneous Leishmaniasis Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3 Departments of Dermatology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
4 Cutaneous Leishmaniasis Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
5 Cutaneous Leishmaniasis Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
6 Departments of Dermatology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
doi
10.22034/ijd.2024.461707.1855چکیده
Background: Solar lentigo is one of the earliest signs of the sun's damaging effects on the skin. Various light-based treatments, including laser therapy, can be used to remove these pigmented lesions. This study aims to evaluate the outcomes of treating solar lentigines using a Q-switched Nd:YAG laser device.Methods: This cross-sectional study was conducted on 50 patients presenting with solar lentigo between 2021 and 2022. The patients received monthly laser treatments for up to five sessions.Results: Treatment of solar lentigo lesions has been associated with a complete or partial response in 98% of cases. The response to treatment in skin phototype II was not statistically significantly different from that in other phototypes (P = 0.068). However, clinically, both patient's and dermatologists' assessments of treatment response at the end of the third session showed a significant relationship with skin phototype (P < 0.001 and P = 0.03, respectively).Conclusion: According to the results, the Q-switched 532 nm Nd:YAG laser may be an effective treatment option for removing solar lentigines. Although it is more expensive than other methods, it could be considered a suitable choice due to its higher success rate and lower complication rate.
